Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

What Was Tested

The trial (phase 3) is built around Tirzepatide and Dulaglutide.

It had three arms (groups): Dulaglutide Group (active comparator), Semaglutide Group (active comparator) and Tirzepatide Group (active comparator).

The registry classes the interventions as drug.

More on the Plan

Monthly follow-up will ensure medication adherence and monitor gastrointestinal adverse events.

Inclusion: BMI \>30, age \>18, non-diabetic.

Exclusion: Diabetes, liver disease, renal dysfunction, pancreatic disease, thyroid disease, psychological disorders, pregnancy.

Who Took Part

150 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Subjects (above 18 years old) obese body mass index (BMI) above 30.

The full record lists 1 inclusion and 1 exclusion criteria; among the exclusions: subjects with liver disease, renal dysfunction diabetes, pancreatic diseases ,thyroid disorder or goiter psychological diseases like depression and pregnant women, and patients who will refuse.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-11-14 with completion listed for 2026-04-13.

It ran at 1 site in Saudi Arabia.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): change in body weight at 3 and 6 months (time frame: Baseline, Week 12 (3 months) and Week 24 (6 months)).

It also tracked 8 secondary outcomes, for example Change in Body Mass Index (BMI), Change in Glycated Hemoglobin (HbA1c), Change in Low-Density Lipoprotein Cholesterol (LDL-C), Change in Triglycerides, Change in High-Density Lipoprotein Cholesterol (HDL-C) and Change in Total Cholesterol (TC).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide and Dulaglutide in 150 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page and the Dulaglutide compound page, all human trials.